Clindamycin Vaginal

78 interactions 680 cited references
Also sold as: Cleocin Cleocin® Vaginal Suppository Clindesse Clindesse® Vaginal Cream
About Clindamycin Vaginal

Vaginal clindamycin is used to treat bacterial vaginosis (an infection caused by an overgrowth of harmful bacteria in the vagina). Clindamycin is in a class of medications called lincomycin antibiotics. It works by slowing or stopping the growth of bacteria. Vaginal clindamycin cannot be used to treat vaginal irritatio… Read the full Clindamycin Vaginal drug information page →

Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Mifepristone Levoketoconazole Ensitrelvir Apalutamide Asciminib Avacopan
3 Contraindicated 57 Major 18 Moderate
All (78) Contraindicated (3) Major (57) Moderate (18)

Major

Clindamycin Vaginal Palbociclib Ibrance Increased exposure to CYP3A substrates with a narrow therapeutic index Details Clindamycin Vaginal Phenobarbital Fidoquel Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Clindamycin Vaginal Primidone Mysoline Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Clindamycin Vaginal Ranolazine Aspruzyo Increased exposure of CYP3A4 substrate Details Clindamycin Vaginal Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Clindamycin Vaginal Repotrectinib Augtyro Reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Clindamycin Vaginal Ribociclib Kisqali Increased exposure of CYP3A4 substrate and an increased risk of CYP3A4 substrate-related adverse reactions Details Clindamycin Vaginal Selpercatinib Retevmo Increased substrate exposure and an increased risk for adverse effects Details Clindamycin Vaginal Sevabertinib Hyrnuo Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Clindamycin Vaginal Sotorasib Lumakras Reduced exposure to CYP3A substrate and an increased risk of therapeutic failure Details Clindamycin Vaginal Suzetrigine Journavx Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Clindamycin Vaginal Taurursodiol Decreased exposure of the CYP3A4 substrate Details Clindamycin Vaginal Tazemetostat Tazverik Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Clindamycin Vaginal Tocilizumab Actemra Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Clindamycin Vaginal Tovorafenib Ojemda Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Clindamycin Vaginal Treosulfan Grafapex Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse and serious life-threatening toxicit... Details Clindamycin Vaginal Tucatinib Tukysa Increased exposure to CYP3A substrate and risk of toxicity Details Clindamycin Vaginal Vonoprazan Voquezna Increased CYP3A substrates exposure Details Clindamycin Vaginal Vorasidenib Voranigo Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Clindamycin Vaginal Voriconazole Vfend Increased CYP3A4 substrates exposure and an increased efficacy of CYP3A4 substrates-related adverse effects Details

Moderate

Clindamycin Vaginal Artemether Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Clindamycin Vaginal Atracurium Enhanced and prolonged neuromuscular blockade Details Clindamycin Vaginal Cisatracurium Enhanced neuromuscular blocking action Details Clindamycin Vaginal Cyclosporine Atopica Decreased cycloSPORINE bioavailability Details Clindamycin Vaginal Doxacurium Enhanced and prolonged neuromuscular blockade Details Clindamycin Vaginal Gallamine Enhanced and prolonged neuromuscular blockade Details Clindamycin Vaginal Kaolin Pet Pectillin Decreased clindamycin effectiveness Details Clindamycin Vaginal Kratom Increased CYP3A substrate exposure Details Clindamycin Vaginal Lixisenatide Delayed therapeutic effect Details Clindamycin Vaginal Mavacamten Camzyos Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Clindamycin Vaginal Metocurine Enhanced and prolonged neuromuscular blockade Details Clindamycin Vaginal Mivacurium Enhanced and prolonged neuromuscular blockade Details Clindamycin Vaginal Pancuronium Pancuronium toxicity (respiratory depression) Details Clindamycin Vaginal Pipecuronium Enhanced and prolonged neuromuscular blockade Details Clindamycin Vaginal Rilzabrutinib Wayrilz Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Clindamycin Vaginal Rocuronium Enhanced and prolonged neuromuscular blockade Details Clindamycin Vaginal Tubocurarine Enhanced and prolonged neuromuscular blockade Details Clindamycin Vaginal Vecuronium Vecuronium toxicity (respiratory depression) Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.